This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
2 Stocks to Watch as Ethereum Shows Promise for 2024
by Abhinab Dasgupta
Accenture (ACN) and CME are two Ethereum-exposed stocks that should be tracked as the bitcoin-rival promises a big 2024.
Insights Into Accenture (ACN) Q1: Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Accenture (ACN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended November 2023.
Here's How Much You'd Have If You Invested $1000 in Accenture a Decade Ago
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Accenture PLC (ACN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Accenture (ACN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Accenture (ACN) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
The latest trading day saw Accenture (ACN) settling at $342.31, representing a +1.51% change from its previous close.
Accenture (ACN) Announces AI Collaboration With Unilever
by Zacks Equity Research
The partnership aims at integrating Accenture's (ACN) expertise and ecosystem of partnerships with Unilever's disruptive innovation.
Accenture (ACN) Stock Moves -0.48%: What You Should Know
by Zacks Equity Research
Accenture (ACN) reachead $336.43 at the closing of the latest trading day, reflecting a -0.48% change compared to its last close.
Is ProShares S&P Technology Dividend Aristocrats ETF (TDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for TDV
Accenture (ACN) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Accenture (ACN) stood at $332.43, denoting a -0.48% change from the preceding trading day.
The Zacks Analyst Blog Highlights Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce
by Zacks Equity Research
Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce are included in this Analyst Blog.